cyclopentane has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faessel, HM; Faller, DV; Mould, DR; Sedarati, F; Venkatakrishnan, K; Zhou, X | 1 |
| Akimoto, M; Honma, Y; Ishii, Y; Ishikura, H; Kiyota, H; Tsumura, H | 1 |
2 other study(ies) available for cyclopentane and Hematologic Malignancies
| Article | Year |
|---|---|
Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Variation, Population; Clinical Trials as Topic; Cyclopentanes; Drug Interactions; Drugs, Investigational; Female; Hematologic Neoplasms; Humans; Male; Metabolic Clearance Rate; Middle Aged; Pyrimidines; Reference Values; Standard of Care; Young Adult | 2019 |
Gene expression profiles in differentiating leukemia cells induced by methyl jasmonate are similar to those of cytokinins and methyl jasmonate analogs induce the differentiation of human leukemia cells in primary culture.
Topics: Acetates; Cell Differentiation; Cyclopentanes; Cytokinins; Esters; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; HL-60 Cells; Humans; Isopentenyladenosine; Leukemia; Oxylipins; Tumor Cells, Cultured | 2009 |